Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
MS4A3 Biologics Sequence Review Report 2026: Membrane-spanning 4-domains subfamily A member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MS4A3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MRC2 Biologics Sequence Review Report 2026: C-type mannose receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MRC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP13 Biologics Sequence Review Report 2026: Collagenase 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP12 Biologics Sequence Review Report 2026: Macrophage metalloelastase Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP11 Biologics Sequence Review Report 2026: Stromelysin-3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP10 Biologics Sequence Review Report 2026: Stromelysin-2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP7 Biologics Sequence Review Report 2026: Matrilysin Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP3 Biologics Sequence Review Report 2026: Stromelysin-1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP2 Biologics Sequence Review Report 2026: 72 kDa type IV collagenase Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP1 Biologics Sequence Review Report 2026: Interstitial collagenase Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MME Biologics Sequence Review Report 2026: Neprilysin Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MME sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MC2R Biologics Sequence Review Report 2026: Adrenocorticotropic hormone receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MC2R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.